IL13RA2 and glioblastoma: Trivalent CAR-T (HER2, IL13Rα2, and EphA2-targeted CAR-T) mediated immunoreaction forming polarized microtubule organizing centers, exhibited improved cytotoxicity and cytokine release, and overcame antigenic heterogeneity in glioblastoma thereby improving treatment outcomes (63).